Cargando…
MED1, a novel binding partner of BRCA1, regulates homologous recombination and R-loop processing
Homologous recombination (HR) is a major repair pathway of DNA double-strand breaks and is closely related to carcinogenesis. HR deficiency has been established as a therapeutic target. The aim of this study was to elucidate the functions of a novel HR factor, Mediator complex subunit 1 (MED1), and...
Autores principales: | Honjoh, Harunori, Tanikawa, Michihiro, Wada-Hiraike, Osamu, Oda, Katsutoshi, Inaba, Hirofumi, Kukita, Asako, Kawata, Yoshiko, Kusakabe, Misako, Tsuchimochi, Saki, Taguchi, Ayumi, Miyamoto, Yuichiro, Sone, Kenbun, Tsuruga, Tetsushi, Mori-Uchino, Mayuyo, Matsumoto, Yoko, Osuga, Yutaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561711/ https://www.ncbi.nlm.nih.gov/pubmed/36229463 http://dx.doi.org/10.1038/s41598-022-21495-8 |
Ejemplares similares
-
Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma
por: Tsuchimochi, Saki, et al.
Publicado: (2023) -
The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells
por: Kojima, Machiko, et al.
Publicado: (2020) -
The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation
por: Kojima, Machiko, et al.
Publicado: (2019) -
Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer
por: Wada, Miku, et al.
Publicado: (2020) -
Recurrent malignant melanoma of the uterine cervix treated with anti-PD-1 antibodies and anti-CTLA-4 antibodies: A case report
por: Sone, Kenbun, et al.
Publicado: (2022)